Global Diabetes Care Devices Market 2026

Insulin pumps grow fastest; CGM delivers the largest revenue gain

Insulin pumps and infusion consumables are forecast to grow at 11.5% annually from 2025 to 2031, supported by automated insulin delivery and conversion from injections. CGM expands at 9.8% and contributes the largest absolute increase in revenue. Together, these two businesses are projected to account for 87.8% of market revenue in 2031.

Traditional fingerstick monitoring retains a role in affordable and supplementary testing, but migration among frequent testers puts pressure on test-strip revenue. Connected insulin pens provide another route to integrating dose records with glucose data. These different adoption paths make reimbursement, compatibility and sustained use central to commercial performance.

Recurring use changes the competitive equation

Sensor replenishment, disposable pods and infusion supplies extend revenue beyond the initial device purchase. Established suppliers benefit from distribution reach and reimbursement access, while new platforms compete on wearability, ease of use and system compatibility. Patient retention and reliable supply influence how adoption translates into repeat revenue.

North America is expected to remain the largest regional market. Asia Pacific is forecast to grow faster, as access expands across markets with different reimbursement arrangements and affordability constraints. The report connects these regional differences with product adoption, payment pathways and manufacturer strategies.

What the report covers

• Annual market sizing: Global revenue estimates for 2025 and annual forecasts for 2026–2031, with four product categories, market totals and category growth rates.
• Product markets: CGM devices and consumables; SMBG meters, strips and associated lancing accessories; insulin pumps and infusion consumables; insulin pen hardware and smart accessories.
• Regional analysis: North America, Europe, Asia Pacific and other regions, including 2025 and 2031 revenue, shares and growth rates.
• Technology and adoption: Automated insulin delivery, patch and durable pumps, implantable monitoring, multi-analyte sensing, connected injection management and the development status of alternative approaches.
• Competition and commercial models: Supplier strategies, system partnerships, reimbursement, recurring consumables, manufacturing and user retention.
• Treatment dynamics: Type 1 and type 2 diabetes pathways, digital care integration and the implications of GLP-1 medicines for device use.

Market revenue measures manufacturer-level device value. Insulin pen figures cover hardware and smart accessories, including the estimated hardware component of prefilled pens, rather than the insulin they contain.

Participants examined

Coverage includes Abbott, Dexcom, Insulet, MiniMed, Tandem, Beta Bionics, Senseonics, Roche, Ascensia/PHC, LifeScan, Sinocare, mylife Diabetes Care, Ypsomed, Sequel Med Tech, Diabeloop, Tidepool, Novo Nordisk, Sanofi and Eli Lilly.

Report contents

1. Market Overview
2. Global Market Size and Growth
3. Product Markets
4. Competitive Landscape and Company Strategies
5. Demand, Reimbursement and Business Models
6. Regional Markets

Delivery details

Format: English PDF
Length: 16 pages
Publication: October 2026
Included: Six tables, three data visualizations and 32 references
Delivery: Automatic digital download after payment